Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has scheduled its first quarter 2025 financial results conference call and webcast for Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time. The company will discuss Q1 2025 financial performance and recent portfolio developments.
The event will be accessible through a live webcast in the Investors & Media section of www.kiniksa.com. Interested participants can register for telephone access, after which they will receive confirmation details including dial-in information and unique access credentials. A replay will be available on the company website within 48 hours after the event.
Kiniksa Pharmaceuticals reported strong ARCALYST sales growth of 79% year-over-year, reaching $417.0 million for full year 2024 and $122.5 million for Q4 2024. The company projects 2025 ARCALYST net product revenue between $560-$580 million.
The company is prioritizing cardiovascular indications in its development pipeline. Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026. KPL-387 offers potential monthly subcutaneous dosing. Additionally, KPL-1161 is advancing toward clinical development with a target of quarterly subcutaneous dosing.
Kiniksa will discontinue development of abiprubart in Sjögren's Disease and has terminated its exclusive license agreement for mavrilimumab with MedImmune. The company reported a net loss of $8.9 million for Q4 2024 and $43.2 million for full year 2024, but expects its current operating plan to remain cash flow positive annually.
Kiniksa Pharmaceuticals announced the development of KPL-387 for recurrent pericarditis, with plans to initiate a Phase 2/3 clinical trial in mid-2025. Phase 1 single ascending dose data supports potential monthly dosing with a subcutaneous injection in liquid formulation.
The company is prioritizing cardiovascular indications in its development strategy while discontinuing abiprubart development in Sjögren's Disease and terminating its mavrilimumab license agreement with MedImmune.
Since launching ARCALYST in 2021 for recurrent pericarditis, Kiniksa has generated over $800 million in product revenue and achieved positive annual cash flow. The company plans to further increase ARCALYST's market penetration while developing KPL-387 to expand treatment options.
Additionally, Kiniksa is advancing KPL-1161, another monoclonal antibody targeting IL-1R1, with a target profile of quarterly subcutaneous dosing.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website. Interested participants can register for telephone access, and a replay will be available on the website within 48 hours after the event.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported preliminary unaudited ARCALYST net product revenue of $416.4 million for 2024, showing approximately 79% year-over-year growth. The company provided 2025 revenue guidance of $560-580 million.
Q4 2024 ARCALYST revenue reached $121.9 million. The drug's uptake in recurrent pericarditis continues to grow, with approximately 13% of the 14,000 multiple-recurrence target population actively on therapy. More than 2,850 prescribers have written ARCALYST prescriptions, with patients maintaining an average treatment duration of 27 months.
The company reported $243.6 million in cash, cash equivalents, and short-term investments as of December 31, 2024, and expects to remain cash flow positive annually.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors and interested parties can access a live webcast of the presentation through the Investors section of Kiniksa's website at www.kiniksa.com. Additionally, a replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:35 a.m. Eastern Time.
The presentation will be accessible via live webcast through the Investors section of Kiniksa's website at www.kiniksa.com. A replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 2024 Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT (7:00 a.m. ET).
Interested parties can access a live webcast of the presentation through the Investors section of Kiniksa's website at www.kiniksa.com. A replay will be made available on the company's website within 48 hours after the event.
Kiniksa Pharmaceuticals reported strong Q3 2024 financial results, with ARCALYST generating net product revenue of $112.2 million, representing 73% year-over-year growth. The company raised its 2024 ARCALYST revenue guidance to $410-420 million. Since its April 2021 launch, over 2,550 prescribers have written ARCALYST prescriptions for recurrent pericarditis, with average therapy duration reaching 27 months. The company reported a Q3 net loss of $12.7 million but maintains $223.8 million in cash and investments with no debt. Kiniksa expects to remain cash flow positive annually while advancing its pipeline, including the Phase 2b trial of abiprubart in Sjögren's Disease.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with GRAMMY Award-winning singer-songwriter Carly Pearce to expand its Life DisRPted™ campaign, focusing on raising awareness for recurrent pericarditis. The campaign aims to promote early diagnosis and treatment of this rare, chronic autoinflammatory disease. Pearce, who was diagnosed with recurrent pericarditis while on tour in May 2024, joins the initiative to support patients and caregivers affected by the condition.
The campaign serves as a platform to encourage both patients and healthcare providers to recognize signs of recurrent pericarditis and develop appropriate treatment plans to minimize its impact on patients' lives. More information about the campaign and the condition can be found at LifeDisRPted.com.